Royalty Pharma (RPRX) EBITDA (2019 - 2026)
Royalty Pharma (RPRX) EBITDA from Jun 30, 2019 to Mar 31, 2026. The TTM Royalty Pharma (RPRX) EBITDA is $1.59B. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Royalty Pharma (RPRX) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | -10.36% |
| 3 Years TTM | +45.28% |
| 5 Years TTM | +11.98% |
| All Time TTM | +7.02% |
Annual EBITDA change of Royalty Pharma (RPRX)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | $564M | -63.91% |
| 2025 | $1.56B | +20.96% |
| 2024 | $1.29B | -13.38% |
| 2023 | $1.49B | +546.54% |
| 2022 | $231M | -70.63% |
| 2021 | $786M | -30.58% |
| 2020 | $1.13B | -56.74% |
| 2019 | $2.62B | +57.88% |
| 2018 | $1.66B | N/A |
Comparison Royalty Pharma (RPRX) five years EBITDA CAGR with competitors
Royalty Pharma (RPRX) five years EBITDA CAGR is 9.12%.